StockData

Zhengye Biotechnology Holding Ltd (ZYBT) income statement

ZYBTNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 28, 2026Score 4/30
$1.50−0.02 (-1.32%)

Close on Nov 18, 2026Market cap $71.09MP/E –Yield –

Zhengye Biotechnology Holding Ltd income statement

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin
20.5%
Operating margin
-60.6%
Net margin
-60.0%
Return on equity, FY2025
-26.1%

Financial strength

Current ratio
1.14
Debt to equity
–
Debt to assets
–
Cash to current liabilities
41.8%

Valuation

P/E ratio
–
Price to sales
4.08
Price to book
1.90
Dividend yield
–

See a number that looks wrong?